Skip to primary content
Skip to secondary content

Biotech 365

Main menu

  • Biotech 365
  • Companies
  • Healthcare Investors
    • Healthcare LPs
  • Healthcare Investors Matchmaking
  • Free DEMO
  • Services
    • Preclinical Studies Database
    • Scientific Due Diligence
    • CRO & CDMO Database
  • Contact

Tag Archives: FFPE-based genomic diagnostic

Agendia – decoding cancer

Posted on by

Agendia is a leading molecular diagnostics company developing FFPE-based genomic diagnostic products, allowing clinically relevant gene expression profiling for cancer patients.

Agendia – decoding cancer

agendia Continue reading →

Posted in Biotech Companies, Biotech Companies Netherlands | Tagged Agendia, Agendia - decoding cancer, Annuska Glas, Antoni van Leeuwenhoek Hospital, Bastiaan van der Baan, Bob Brousseau, breast cancer, breast cancer recurrence assay, cancer diagnosis, Colin Goddard, ColoPrint 18-Gene Colon Cancer Recurrence Assay, decoding cancer, Dharminder Chahal, DNA microarray, FFPE-based genomic diagnostic, FFPE-based genomic diagnostics, gene expression profiling, Glen Fredenberg, Guido Brink, Harry Bartelink, Hessel Lindenbergh, ISPY-2, ISPY2, Jan Egberts, Jeffrey Jones, Laura van ‘t Veer, MammaPrint, MammaPrint 70-gene, MammaPrint 70-gene Breast Cancer, MammaPrint 70-gene Breast Cancer Recurrence Assay, MammaPrint Breast Cancer, metastasis, MicroarRAy PrognoSTics in Breast CancER, MINDACT, Neil Barth, Netherlands Cancer Institute, Peter Schineller, Pieter van der Meer, RASTER, René Bernards, Thomas Vanhoutte

        Services              Healthcare Investors Database              FAQs               CGU               Biotech & Pharma News             Contact
Proudly powered by WordPress